Dermira was a biopharmaceutical company that focused on developing new treatments for chronic skin conditions. In 2020, Eli Lilly and Company acquired Dermira, acquiring its lead product, Qbrexza (glycopyrronium), and its pipeline including lebrikizumab, a monoclonal antibody for atopic dermatitis.